Publication | Closed Access

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

Second-line TreatmentAdvanced Breast CancerBreast OncologyOncologyMedicineClinical TrialsBreast CancerPharmacotherapyCancer TreatmentPharmacology